Degrader Radar, Apr. ’23: DCAF1, on CNS Degraders, and More

This article highlights six recent articles of interest in the field of targeted protein degradation including but not limited to potentially new ligases, recruiting motifs, and a discussion on the feasibility of CNS-penetrant degraders.

1. “Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings”

Novartis, Basel, CH + Cambridge, MA
BioRxiv, April 14, 2023

DBt-10 Novartis DCAF1-based Degrader

This Novartis study identified a novel non-covalent ligand for the E3 ligase receptor DCAF1 for use in targeted protein degradation and developed several proof-of-concept PROTACs including a potent and selective DCAF1-BTK PROTAC (DBt-10) that can overcome resistance to CRBN-based degradation. These findings highlight the versatility of DCAF1 for TPD and offer a new avenue for developing therapies for diseases where catalytic inhibition is not an option.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!